ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,078.81
-0.17%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) Noticias

CANF Can Fite BioPharma Ltd

3.35
-0.28 (-7.71%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Can Fite BioPharma Ltd CANF AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.28 -7.71% 3.35 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.76 3.10 4.48 3.35 3.63
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
10/6/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/6/202406:00BWCan-Fite Received IRB Approval for the Treatment of..
07/6/202415:15EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
05/6/202406:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202406:00BWCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase..
29/5/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202406:00BWIndependent Scientists Published a Review Article..
27/5/202406:00BWCan-Fite to Participate in Partnering Meetings at Bio..
23/5/202406:00BWJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
22/5/202415:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202406:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202406:00BWCan-Fite: 75 Oncologists and Coordinators from Europe US and..
09/5/202406:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202406:00BWCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat..
06/5/202406:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202406:00BWCan-Fite Received Notice of Allowance from the European..
25/4/202406:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15/4/202406:00BWCan-Fite: Scientific Article Published by KOL Presents..
03/4/202406:00BWCan-Fite: Submits FDA with an IND Application to Conduct..
28/3/202406:00BWCan-Fite Reports 2023 Financial Results and Clinical Update
11/3/202406:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202406:00BWNamodenoson Treatment for Pancreatic and Liver Cancer: Data..
28/2/202406:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202406:00BWCan-Fite Broadens its Strong Intellectual Property (IP) for..
14/2/202414:32EDGAR2Form SC 13G - Statement of acquisition of beneficial..
30/1/202406:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202406:00BWCan-Fite Expands the Out-Licensing Deal with Ewopharma to..
29/1/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202406:00BWCan-Fite: Top Scientific Journal Published Positive Data..
07/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202315:16EDGAR2Form F-3/A - Registration statement by foreign private..
20/12/202306:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202306:00BWThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular..
18/12/202306:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202306:00BWCan-Fite Received FDA Positive Response to Psoriasis..
12/12/202315:15EDGAR2Form F-3 - Registration statement by foreign private issuers
04/12/202306:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202306:00BWCan-Fite’s Namodenoson for the Treatment of Pancreatic..
30/11/202306:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202306:00BWCan-Fite Reports Third Quarter 2023 Financial Results and..
22/11/202315:20EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202312:53GLOBECan-Fite Announces Exercise of Warrants for Approximately..
21/11/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202306:00BWCan-Fite: Complete Response and 6.9 Years Overall Survival..
01/11/202306:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202306:00BWCan-Fite Issues Business Update: All Clinical Programs and..
30/10/202306:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202306:00BWCan Fite: Namodenoson Inhibits Pancreatic Carcinoma..

Su Consulta Reciente

AMEX
CANF
Can Fite BioPharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados